NGS Analysis of the BRCA1/BRCA2 Variants in the Ovarian Cancer Patients at High versus Low Risk of Mutation
Article Sidebar
Main Article Content
Abstract
Objectives: The pathogenic variant in breast cancer susceptibility gene 1/2 (BRCA1/2) is related to the risk of ovarian cancer, which is one of the most common cancers among women worldwide. Here, we aimed to understand the variants of these genes among Vietnamese population to improve early detection and diagnosis as well as treatment decisions.
Materials and Methods: BRCA1/2 genes of tumor tissue from 33 ovarian cancer patients in high-risk and low-risk of mutation groups were sequenced by next-generation sequencing (NGS) using the BRCAaccuTestTM PLUS kit.
Results: Among a total of 33 distinguished variants detected, we found 5 pathogenic and likely pathogenic (P/LP) variants, including c.1801_1808delCACAATTC, c.1016delA, c.1673_1674delAA, c.928C>T in BRCA1 and c.2865delC in BRCA2 with a frequency of 3.03%, except for c.1801_1808delCACAATTC (6.06%). All variants led to defects in coding protein. c.1801_1808delCACAATTC variant in BRCA1 and c.2865delC in BRCA2 was firstly introduced. The prevalence of BRCA1/2 P/LP variants in the high-risk group was 22.73%, while this figure for the low-risk group was 9.09%. No statistically significant difference in other clinical features was found between P/LP variant-carried and non-P/LP variant-carried patients apart from age and comorbidities.
Conclusions: This study provided precious data for BRCA1/2 variant mapping among Vietnamese ovarian cancer patients.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-49.
Stewart C, Ralyea C, Lockwood S. Ovarian cancer: An integrated review. Semin Oncol Nurs 2019;35:151-6.
Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 2004;3:355-66.
Chandra A, Pius C, Nabeel M, Nair M, Vishwanatha JK, Ahmad S, et al. Ovarian cancer: Current status and strategies for improving therapeutic outcomes. Cancer Med 2019;8:7018-31.
Chu DT, Vu Ngoc Suong M, Vu Thi H, Vu TD, Nguyen MH, Singh V. The expression and mutation of BRCA1/2 genes in ovarian cancer: a global systematic study. Expert Rev Mol Diagn 2023;23:53-61.
Chu DT, Ngoc SMV, Thi YVN, Nguyen MA, Van BP, Chinh LT, et al. The gene expression and mutations in ovarian cancer: Current findings and applications. In: Interdisciplinary cancer research. Cham: Springer International Publishing; 2023. p. 1-19.
Karin K, Kerstin R, Barbara W, Eric H, Jan H, Britta B, et al. Prevalence of germline mutations in 21 401 families with breast and ovarian cancer. J Med Genet 2016;53:465.
Carter NJ, Marshall ML, Susswein LR, Zorn KK, Hiraki S, Arvai KJ, et al. Germline pathogenic variants identified in women with ovarian tumors. Gynecol Oncol 2018;151:481-8.
Candido-dos-Reis FJ, Song H, Goode EL, Cunningham JM, Fridley BL, Larson MC, et al. Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer. Clin Cancer Res 2015;21:652-7.
Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: Results from prospective analysis of EMBRACE. J Natl Cancer Inst 2013;105:812-22.
Wang J, Dean DC, Hornicek FJ, Shi H, Duan Z. RNA sequencing (RNA-Seq) and its application in ovarian cancer. Gynecol Oncol 2019;152:194-201.
Jones MA, Timms KM, Hatcher S, Cogan ES, Comeaux MS, Perry M, et al. The landscape of BRCA1 and BRCA2 large rearrangements in an international cohort of over 20 000 ovarian tumors identified using next-generation sequencing. Genes Chromosomes Cancer 2023;62:589-96.
Concolino P, Gelli G, Rizza R, Costella A, Scambia G, Capoluongo E. BRCA1 and BRCA2 testing through next generation sequencing in a small cohort of italian breast/ovarian cancer patients: Novel pathogenic and unknown clinical significance variants. Int J Mol Sci 2019;20.
Sokolenko AP, Bakaeva EK, Venina AR, Kuligina ES, Romanko AA, Aleksakhina SN, et al. Ethnicity-specific BRCA1, BRCA2, PALB2, and ATM pathogenic alleles in breast and ovarian cancer patients from the North Caucasus. Breast Cancer Res Treat 2024;203:307-15.
Manrriquez E, Chapman JS, Mak J, Blanco AM, Chen L-m. Disparities in genetics assessment for women with ovarian cancer: Can we do better? Gynecol Oncol 2018;149:84-8.
Dinh-Toi Chu, Ngoc Quang Nguyen, Nhat-Le Bui, Thuy Duong Vu. Next generation sequencing for the formalin-fixed, paraffin-embedded samples of ovarian cancer in Vietnam. J Adv Biotechnol Exp Ther 2023; 6: 701-10.
Kim MJ, Song BJ, Kim SE, Lee CS, Im J-E, Oh E, et al. 임상검체에서 BRCA 돌연변이를 검출하는 차세대염기서열분석법의 임상적 효용성 평가. lmo 2021;11:283-9.
Hall MJ, Reid JE, Burbidge LA, Pruss D, Deffenbaugh AM, Frye C, et al. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer 2009;115:2222-33.
Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA 2015;313:1347-61.
Sanchez-Lorenzo L, Salas-Benito D, Villamayor J, Patino-Garcia A, Gonzalez-Martin A. The BRCA Gene in epithelial ovarian cancer. Cancers (Basel) 2022;14:1235.
Le TN, Tran VK, Nguyen TT, Vo NS, Hoang TH, Vo HL, et al. BRCA1/2 mutations in vietnamese patients with hereditary breast and ovarian cancer syndrome. Genes (Basel) 2022;13.
Kanchi KL, Johnson KJ, Lu C, McLellan MD, Leiserson MDM, Wendl MC, et al. Integrated analysis of germline and somatic variants in ovarian cancer. Nat Commun 2014;5:3156.
Mafficini A, Simbolo M, Parisi A, Rusev B, Luchini C, Cataldo I, et al. BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing. Oncotarget 2016;7: 1076–83.
Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, Dobrovic A, Birrer MJ, Webb PM, Stewart C, Friedlander M, Fox S, Bowtell D, Mitchell G. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30:2654-63.
Byrum AK, Vindigni A, Mosammaparast N. Defining and modulating ‘BRCAness’. Trends Cell Biol 2019;29:740-51.
Vergote I, Denys H, Altintas S, Kerger J, Baurain JF, Bours V, et al. Homologous recombination repair deficiency (HRD) testing in newly diagnosed advanced-stage epithelial ovarian cancer: A Belgian expert opinion. Facts Views Vis Obgyn 2022;14:111-20.
Hamdi Y, Mighri N, Boujemaa M, Mejri N, Ben Nasr S, Ben Rekaya M, et al. Identification of eleven novel BRCA mutations in Tunisia: Impact on the clinical management of BRCA related cancers. Front Oncol 2021;11:674965.
Liu W, Wang Z, Ma J, Hou Y, Zhao J, Dong B, et al. Elevated serum level of CA125 is a biomarker that can be used to alter prognosis determined by BRCA mutation and family history in ovarian cancer. Genet Test Mol Biomarkers 2017;21:547-54.
Soegaard M, Kjaer SK, Cox M, Wozniak E, Høgdall E, Høgdall C, et al. BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark. Clin Cancer Res 2008;14:3761-7.
Han E, Yoo J, Chae H, Lee S, Kim D-H, Kim KJ, et al. Detection of BRCA1/2 large genomic rearrangement including BRCA1 promoter-region deletions using next-generation sequencing. Clinica Chimica Acta 2020;505:49-54.